Epidermal growth factor receptor (EGFR) tumor-specific conformational epitope

The Epidermal Growth Factor Receptor (EGFR) tumor-specific conformational epitope is a unique structural site located within the extracellular domain of the receptor, specifically involving residues 287–302 in domain II (Johns et al., 2002, J Biol Chem). In healthy tissues, wild-type EGFR typically resides in a \tethered\ autoinhibited conformation that keeps this epitope hidden from circulating antibodies (Garrett et al., 2009, PNAS). In many malignancies, such as glioblastoma, the receptor is either overexpressed or mutated (e.g., EGFRvIII), causing it to adopt an \untethered\ or active conformation that exposes this cryptic epitope (Gan et al., 2012, FEBS J). This differential exposure provides a significant therapeutic window, allowing drugs to selectively target tumor cells while sparing normal tissues like the skin and liver where EGFR is abundant but tethered (Chao et al., 2004, Cancer Res). Therapeutic strategies targeting this epitope include monoclonal antibodies like mAb 806 and antibody-drug conjugates (ADCs) such as Depatuxizumab mafodotin (Lassman et al., 2017, Neuro-Oncology). These agents work by delivering cytotoxic payloads or inhibiting downstream oncogenic signaling pathways, including the PI3K/Akt and MAPK cascades (Phillips et al., 2016, Mol Cancer Ther). Clinical trials have primarily investigated these therapies in patients with EGFR-amplified glioblastoma and other solid tumors (Van Den Bent et al., 2020, Lancet Oncol). While the specificity for tumor tissue is high, some clinical challenges have emerged, most notably ocular toxicities associated with the microtubule-disrupting payloads used in ADCs (Parakh et al., 2017, Expert Opin Biol Ther).

Other names

806 epitopeEGFR cryptic epitopeEGFRvIII-specific epitopemAb 806 binding siteEGFR residues 287-302

Selective binding to the exposed cysteine-rich domain II of EGFR in its untethered or mutated state, leading to inhibition of downstream signaling, induction of antibody-dependent cellular cytotoxicity (ADCC), or targeted delivery of cytotoxic conjugates directly to tumor cells.